The Effect of Vitamin D Levels in Multisystem Inflammatory Syndrome in Children

Ahmet Kan; Mehmet Türe; Alper Akın; Kamil Yılmaz; Mehmet Sürücü; Edip Ünal; Velat Şen; Veysiye Hülya Üzel

doi:10.1055/s-0042-1749372

Journal of Pediatric Infectious Diseases, Table of Contents

J Pediatr Infect Dis 2022; 17(04): 194-199
DOI: 10.1055/s-0042-1749372

Original Article

The Effect of Vitamin D Levels in Multisystem Inflammatory Syndrome in Children

Ahmet Kan

¹Department of Pediatric Allergy and Immunology, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

,

Mehmet Türe

²Department of Pediatric Cardiology, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

,

Alper Akın

²Department of Pediatric Cardiology, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

,

Kamil Yılmaz

³Department of Pediatrics, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

,

Mehmet Sürücü

³Department of Pediatrics, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

,

Edip Ünal

⁴Department of Pediatric Endocrinology, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

,

Velat Şen

⁵Department of Pediatric Pulmonology, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

,

Veysiye Hülya Üzel

⁶Department of Pediatric Hematology, Dicle University Faculty of Medicine, Dicle University, Diyarbakır, Turkey

› Author Affiliations

Abstract

Objective Multiple factors being overweight, asthmatic, or being of Asian or black ethnic origins have been reported vis-à-vis the “multisystem inflammatory syndrome in children” (MIS-C). There is an association between these conditions and vitamin D deficiency, which explains why MIS-C is more common in these patients. In the present study, we attempted to retrospective evaluate the 25-hydroxy vitamin D levels of patients with MIS-C, its association with acute phase reactants, its treatment, and clinical status.

Methods Patients aged between 1.5 months to 18 years with MIS-C were included in the study. All of the laboratory parameters, treatment, and response to the treatment were evaluated retrospectively. Two groups were formed. Patients had 25‐hydroxycholecalciferol D vitamin < 20 ng/mL in group 1 and ≥ 20 ng/mL in group 2.

Results A total of 52 patients were included in the study. There was no statistical difference between groups in terms of acceptance of the intensive care unit treatment (p = 0.29) and response to the first-line treatment (p = 0.56). A lower median lymphocyte count (p = 0.01) and a higher median C-reactive protein (p = 0.04) and procalcitonin (p = 0.01) with N-terminal pro-B-type natriuretic peptide (p = 0.025) values were found in group 1.

Conclusion Vitamin D deficiency was associated with an increased inflammatory response in children with MIS-C. More studies are required to determine the potential impact of vitamin D deficiency on the clinical outcome of MIS-C.

Keywords

multisystem inflammatory syndrome - vitamin D - inflammation parameters

Full Text

References

References
1 Whittaker E, Bamford A, Kenny J. et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324 (03) 259-269
2 WHO. Multisystem inflammatory syndrome in children and adolescents with COVID19: scientific brief. World Health Organization. Geneva: 2020 . Accessed August 26, 2020 at: https://apps.who.int/iris/handle/10665/332095
3 Licciardi F, Baldini L, Denina M. et al. Peculiar immunophenotypic signature in MIS-C-affected children. Pediatr Allergy Immunol 2021; 32 (04) 801-804
4 Tsabouri S, Makis A, Kosmeri C, Siomou E. Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review. Pediatr Clin North Am 2021; 68 (01) 321-338
5 Grant WB, Lahore H, McDonnell SL. et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 2020; 12 (04) 988
6 Feketea G, Vlacha V, Bocsan IC, Vassilopoulou E, Stanciu LA, Zdrenghea M. Vitamin D in corona virus disease 2019 (COVID-19) related multisystem inflammatory syndrome in children (MIS-C). Front Immunol 2021; 12: 648546
7 Yılmaz K, Şen V. Is vitamin D deficiency a risk factor for COVID-19 in children?. Pediatr Pulmonol 2020; 55 (12) 3595-3601
8 Stagi S, Rigante D, Lepri G, Matucci Cerinic M, Falcini F. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities?. Clin Rheumatol 2016; 35 (07) 1865-1872
9 Hara T, Nakashima Y, Sakai Y, Nishio H, Motomura Y, Yamasaki S. Kawasaki disease: a matter of innate immunity. Clin Exp Immunol 2016; 186 (02) 134-143
10 Lee PY, Day-Lewis M, Henderson LA. et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest 2020; 130 (11) 5942-5950
11 Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10 (04) 482-496
12 Zhang Y, Leung DY, Richers BN. et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012; 188 (05) 2127-2135
13 Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients 2015; 7 (06) 4240-4270
14 Meyer K, Volkmann A, Hufnagel M. et al. Breastfeeding and vitamin D supplementation reduce the risk of Kawasaki disease in a German population-based case-control study. BMC Pediatr 2019; 19 (01) 66
15 Jun JS, Jung YK, Lee DW. Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease. Korean J Pediatr 2017; 60 (07) 216-220
16 Fabi M, Filice E, Biagi C. et al. Multisystem inflammatory syndrome following SARS-CoV-2 infection in children: one year after the onset of the pandemic in a high-incidence area. Viruses 2021; 13 (10) 2022
17 Harwood R, Allin B, Jones CE. et al; PIMS-TS National Consensus Management Study Group. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health 2021; 5 (02) 133-141
18 Yeşiltepe-Mutlu G, Aksu ED, Bereket A, Hatun Ş. Vitamin D status across age groups in Turkey: results of 108742 samples from a private laboratory. J Clin Res Pediatr Endocrinol 2020; 12 (03) 248-255
19 Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep 2020; 10 (01) 20191
20 Darren A, Osman M, Masilamani K. et al. Vitamin D status of children with paediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS-TS). Br J Nutr 2022; 127 (06) 896-903
21 Martinez OM, Bridges ND, Goldmuntz E, Pascual V. The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. Nat Med 2020; 26 (12) 1819-1824
22 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73 (04) e13-e29
23 Nijman RG, De Guchtenaere A, Koletzko B. et al. Pediatric inflammatory multisystem syndrome: statement by the Pediatric Section of the European Society for Emergency Medicine and European Academy of Pediatrics. Front Pediatr 2020; 8: 490
24 Abrams JY, Oster ME, Godfred-Cato SE. et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health 2021; 5 (05) 323-331
25 Daneshkhah A, Agrawal V, Eshein A, Subramanian H, Roy HK, Backman V. Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients. Aging Clin Exp Res 2020; 32 (10) 2141-2158
26 Zhou Y-F, Luo B-A, Qin L-L. The association between vitamin D deficiency and community-acquired pneumonia: a meta-analysis of observational studies. Medicine (Baltimore) 2019; 98 (38) e17252
27 Dalvi SM, Ramraje NN, Patil VW, Hegde R, Yeram N. Study of IL-6 and vitamin D3 in patients of pulmonary tuberculosis. Indian J Tuberc 2019; 66 (03) 337-345
28 Lu D, Zhang J, Ma C. et al. Link between community-acquired pneumonia and vitamin D levels in older patients. Z Gerontol Geriatr 2018; 51 (04) 435-439
29 Panfili FM, Roversi M, D'Argenio P, Rossi P, Cappa M, Fintini D. Possible role of vitamin D in Covid-19 infection in pediatric population. J Endocrinol Invest 2021; 44 (01) 27-35
30 Absoud M, Cummins C, Lim MJ, Wassmer E, Shaw N. Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. PLoS One 2011; 6 (07) e22179
31 Cashman KD, Dowling KG, Škrabáková Z. et al. Vitamin D deficiency in Europe: pandemic?. Am J Clin Nutr 2016; 103 (04) 1033-1044